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CCR5Temporal lobe epilepsy (TLE) is one of the most common focal epilepsy syndromes. In a genome-wide ex-
pression study of the human TLE hippocampus we previously showed up-regulation of genes involved in che-
mokine signalling. Here we investigate in the rat pilocarpine model for TLE, whether changes in chemokine
signalling occur during epileptogenesis and are persistent. Therefore we analysed hippocampal protein ex-
pression and cellular localisation of CCL2, CCL4, CCR1 and CCR5 after status epilepticus. We found increased
CCL4 (but not CCL2) expression in speciﬁc populations of hilar astrocytes at 2 and 19 weeks after SE concom-
itant with a persistent up-regulation of its receptor CCR5. Our results show an early and persistent up-
regulation of CCL4/CCR5 signalling during epileptogenesis and suggest that CCL4 signalling, rather than
CCL2 signalling, could have a role in the epileptogenic process.
© 2012 Elsevier B.V. Open access under the Elsevier OA license.1. Introduction
Temporal lobe epilepsy (TLE) is a debilitating disease with a high
percentage of patients that do not respond to the conventional anti-
epileptic drugs (Kwan and Brodie, 2003; Cascino, 2008). Current
anti-epileptic drug treatment is limited to suppressing seizure activi-
ty, and does not interfere with the actual disease process (Temkin,
2001; Loscher and Schmidt, 2006; Stafstrom, 2010). TLE is a type of
epilepsy that can involve an early precipitating event such as head
trauma, febrile seizures and sometimes status epilepticus (SE), this
event is subsequently followed by a latent phase in which no clinical
seizure activity is present (Hauser et al., 1991; Mathern et al., 1995;
Pitkanen and Sutula, 2002; Buchhalter, 2011). During this latent
phase epileptogenic processes are progressing however, and eventu-
ally lead to spontaneous recurrent seizures (SRS). The nature of the
epileptogenic molecular changes during the latent phase is largely
unknown. It has been proposed that activation of the immune system
is involved in epileptogenesis (Vezzani and Granata, 2005; Vezzani et
al., 2011). Findings in both TLE patients and experimental animal
models indicate a rapid increase in expression of components of the
innate immune system in response to seizure activity (Ravizza et al.,
2005; Vezzani and Granata, 2005; Gorter et al., 2006; Ravizza et al.,
2007). This increase can persist for days, even weeks after an epileptic+31 88 7569032.
. de Graan).
this work.
vier OA license.insult, thus exceeding the time course of conventional pro-
inﬂammatory expression experienced after non-epileptic brain in-
sults such as ischemia or lipopolysaccharide injection (Rivest, 2003;
Vezzani and Granata, 2005). Genome-wide expression proﬁling of
the human mTLE hippocampus revealed activation of the innate im-
mune system (Lee et al., 2007; van Gassen et al., 2008) with a marked
increase in mRNA expression of members of the CC chemokine
family.
Chemokines are small secreted proteins that are typically known
for their strong chemotactic properties toward immune cells
(Murdoch and Finn, 2000). The family is divided into 4 groups
based on the relative position of the ﬁrst N-terminal cysteine (CC,
CXC, CX3X and C or δ families), with the CC and CXC being the largest
subgroups (Bajetto et al., 2002). Chemokines activate target cells
through G-protein coupled receptors, often causing an inﬂux of Ca2
+ and the activation of numerous signal transduction pathways
(Biber et al., 2006). Aside from their immunological function, chemo-
kines have been implicated in neural progenitor proliferation and mi-
gration during the central nervous system (CNS) development (Tran
and Miller, 2003). In the adult CNS some chemokines remain
expressed in selected areas where they are thought to play a role in
regulation of neuronal and glial signalling and promotion of cell sur-
vival (Biber et al., 2002; van Gassen et al., 2005; Ransohoff, 2009;
Kuijpers et al., 2010).
Although evidence for a role of chemokine signalling in the path-
ogenesis of epilepsy is accumulating (Fabene et al., 2010), more ex-
perimental evidence in support of this hypothesis is required. Most
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tissue (Lee et al., 2007; van Gassen et al., 2008) or in experimental
models for TLE shortly after SE (Galasso et al., 1998; Mennicken et
al., 2002; Manley et al., 2007; Foresti et al., 2009; Louboutin et al.,
2011). Only a limited number of studies monitored chemokine
mRNA expression proﬁles during the latent and chronic phase
(Gorter et al., 2006; Guzik-Kornacka et al., 2011). Longitudinal studies
in experimental TLE on chemokine protein expression are even more
sparse (Guzik-Kornacka et al., 2011).
In the present study we investigated protein expression of chemo-
kines CCL2 and CCL4 and their receptors CCR1 (receptor for CCL2 and
4) and CCR5 (preferred receptor for CCL4) during the latent and
chronic phase of experimental TLE using immunohistochemistry.
We determined hippocampal expression of these chemokines and
their receptors 2, 4, 8 and 19 weeks after Li+/pilocarpine-induced sta-
tus epilepticus (SE) in rats (Sankar et al., 1998; Roch et al., 2002;
Sloviter, 2008; Leroy et al., 2011) and identiﬁed the cell types expres-
sing them. To allow comparison with cytokine expression, we also de-
termined immunoreactivity in the same hippocampi for interleukin
IL-6, which has previously been implicated in both human and animal
TLE (Peltola et al., 2000; Vezzani and Granata, 2005; Liimatainen et
al., 2009; Vezzani et al., 2011). We show a prolonged up-regulation
of CCL4 (but not CCL2) and its receptors CCR5, and of interleukin IL-
6 after SE.
2. Materials and methods
2.1. Li+/pilocarpine-induced status epilepticus
Male Wistar rats (Charles River Laboratories, Schulzﬁeld, Germa-
ny) arrived at postnatal day 8 (P8) in litters of ten pups. Rats were
weaned and housed individually at P21 and kept in temperature
and humidity controlled rooms on a 12-h normal light schedule
(lights on at 7:00 AM) with food (normal lab chow) and water
ad libitum. All experimental procedures were approved and per-
formed in accordance with the regulations of the Ethical Committee
for Animal Experiments of Utrecht University, The Netherlands.
Experimental SE was induced as described by Sankar et al. (1998).
Brieﬂy, lithium chloride (Li+) (3 mg/kg; Merck, Darmstadt, Germany)
was administered by intraperitoneal (i.p.) injection to all rats 18–20 h
before the subcutaneous injection of pilocarpine (40 mg/kg; Sigma,
St. Louis, MO, USA).
At P21 the animals were injected i.p. with methyl-scopolamine
(1 mg/kg; Sigma, St. Louis, MO, USA) to reduce peripheral effects of
pilocarpine administration. Rats were placed individually in high
plastic cages for behavioural observation. Thirty minutes later pilo-
carpine or an equal volume of saline was administered subcutaneous-
ly. Rat behaviour was classiﬁed in six stages according to Racine
(1972). After one hour of SE, rats received an injection with diazepam
(4 mg/kg i.p., Centrafarm Services BV, Etten-Leur, The Netherlands) to
suppress seizures and reduce mortality rate. Only rats that reached
stage 6 seizures (71%) were included as SE animals in this study.
SRS were detected after a period of 15–18 weeks using daily video
monitoring. Animals were also checked several times a day for
handling-induced seizures. SRS were detected in 44% of SE animals.
It should be noted that this percentage probably is an underestima-
tion as in some animals subclinical seizures occur.
2.2. Immunohistochemistry
Rats were sacriﬁced 2, 4, 8 and 19 weeks after SE (n=6 animals
per time point) or saline treatment (n=5 animals per time point)
by i.p. injection of pentobarbital (300 mg/kg i.p. pentobarbital, Ceva
Sante Animale, Maassluis, The Netherlands) and perfused transcar-
dially with saline containing 500 units heparin (Leo Pharmaceutical
Products, Weesp, The Netherlands) followed by ice-cold ﬁxative (4%paraformaldehyde in 0.1 M phosphate buffer, pH 7.4). Brains were
dissected immediately after perfusion, and post-ﬁxed in the same ﬁx-
ative at 4 °C, dehydrated and embedded in parafﬁn.
Immunohistochemistry (IHC) was performed on 7 μm adjacent
sections with commercially available polyclonal goat antibodies for
CCL2 (1:300), CCL4 (1:300), CCR1 (1:200), CCR5 (1:400), IL-6
(1:300) (Santa Cruz Biotechnology, Santa Cruz, USA) and polyclonal
rabbit anti-Iba1 (WAKO Pure chemicals, Neuss, Germany). Antibody
dilution curves were prepared to determine optimal working concen-
trations. No immunoreactivity (IR) was observed when testing the
immune-antibodies for their speciﬁcity by incubating sections with
primary antibodies preabsorped with excess of their respective anti-
gen, or completing the protocol without the primary antibody (data
not shown).
After rehydration, all sections were subjected to antigen retrieval
using microwave treatment (in 0.01 M, sodium citrate pH 6.0). Non-
speciﬁc binding was blocked with 0.3% H202 for 30 min at room tem-
perature, followed by incubation with foetal calf serum (CCL2, CCR1
and 5 and IL-6) or normal rabbit serum (CCL4) for 30 min at 37 °C.
The primary antibodies were diluted in phosphate buffered saline
(PBS) containing 0.2% Triton-X100/0.1% bovine serum albumin and
sections were incubated overnight at 4 °C. The secondary antibody
was biotinylated rabbit-anti-goat (Dako Cytomation, Glostrup,
Denmark). IR was visualized using the avidin-biotin method (Vectas-
tain ABC Elite kit; Vector Laboratories) with 3,3′-diaminobenzidinete-
trachloride (DAB) as the chromogen (Sigma Chemical Co., St. Louis,
MO). Sections were either counterstained brieﬂy with haematoxylin
(CCL4, CCR5), or directly dehydrated and coverslipped.
2.3. Quantiﬁcation of immunohistochemistry
All sections at each time point were ﬁrst analysed by two indepen-
dent observers blinded for the experimental design. Sections were
ranked according to the intensity of IR in a particular hippocampal
subﬁeld. This analysis revealed that SE-induced expression differ-
ences were most pronounced in the hilar region. IR in this region of
the hippocampus (deﬁned as the area between the two arms of the
granular layer of the dentate gyrus (DG)) was quantiﬁed by comput-
erized densitometry using Image J (Image processing and analysis in
JAVA, version 1.44p). After background correction, relative optical
densities (RODs) were determined and normalized to the respective
age-matched control group. RODs were expressed as mean +/−
standard error of the mean (SEM). Statistical signiﬁcance was tested
within the age group using a 2-tailed Student's T-test (normally dis-
tributed data) or a Mann–Whitney U test (not normally distributed
data) using SPSS (15.0 for windows).
2.4. Immunoﬂuorescence
Double immunoﬂuorescence labelling was performed with a pro-
tocol similar to that for IHC (omitting the 0.3% H202 blocking step).
The secondary antibodies were donkey-anti-goat Alexa 488 (Invitro-
gen, Molecular Probes, Oregon, USA) for CCL2 (1:100) and 4 (1:150),
CCR5 (1:120) and IL-6 (1:100), donkey-anti-rabbit Alexa 555 (Invi-
trogen, Molecular Probes, Oregon, USA) for GFAP (1:6000 Dako Cyto-
mation, Glostrup, Denmark) and Iba1 (1:1500), and donkey-anti-
mouse Alexa 555 (Invitrogen, Molecular Probes, Oregon, USA) for
NeuN (1:800, Chemicon, Illinois, USA) and Vimentin (1:600, Dako
Cytomation, Glostrup, Denmark).
2.5. Microscopy
Images were taken using Axioscop 1 and Axiovert 2 microscopes
(Carl Zeiss). Confocal images were collected in 0.94 μm stacks by a
Confocal Laser Scanning Microscope (CSLM; Olympus FV1000)
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objective.3. Results
3.1. CCL2
Hippocampal CCL2 IR was predominantly detected in the granular
layer of the dentate gyrus (DG) and pyramidal layers of all the Cornu
Ammonis regions (CA) in both control and SE rats (Fig. 1A). Visual as-
sessment of CCL2 IR did not reveal differences in any subﬁeld of the
hippocampus between SE animals and age-matched controls at any
time-point after SE. Furthermore, quantiﬁcation of CCL2 IR in theFig. 1. Longitudinal expression patterns of IR for chemokine signalling proteins after SE.Phot
(A) and CCL4 (B), chemokine receptors CCR1 (C) and CCR5 (D), interleukin IL-6 (E) and m
treated controls (2w). Note IR up-regulation is predominantly found in the hilar region (h). C
radiatum (SR) 8 and 19 weeks after SE. CCL4 and CCR5 IR is counterstained with haematoxhilus did not reveal differences between SE animals and age-
matched controls at any of the time-points after SE (Fig. 2A).
To identify the cell types expressing CCL2 we performed double
labelling experiments using markers for four major CNS cell types.
The majority of CCL2 IR cells also expressed the neuronal marker
NeuN, 2 and 19 weeks after SE (Fig. 3A and B). GFAP-positive glial
cells and Vimentin-positive reactive astroglia were found in very
close proximity to CCL2-positive cells, yet no actual co-labelling was
detected. Additionally, Iba1-positive microglia almost enveloped
CCL2 IR cells. At 2 and 19 weeks after SE a small percentage of Iba1-
positive cells expressed both markers (Fig. 3A, B). This co-
expression was only detected in the hilar region of the hippocampus.
These ﬁndings show that in the rat hippocampus CCL2 is predomi-
nantly expressed in neurons and that its expression is not affected 2omicrographs of the hippocampus showing typical examples of IR of chemokines CCL2
icroglial marker Iba1 (F) at 2, 8 and 19 weeks (2 w, 8 w and 19 w) after SE and saline
CR5 and IL-6 IR up-regulation is also found in the molecular layer (ML) and the stratum
ylin. Scale bar=500 μm.
Fig. 2. Quantiﬁcation of hilar IR for chemokine signalling proteins at various time-points after SE.Relative optical densities (ROD) of the hilar IR for CCL2 (A), CCL4 (B), CCR1 (C),
CCR5 (D), IL-6 (E) and Iba1 (F) were determined at 2w, 4w, 8 w and 19 weeks after SE (n=6 animals per time-point). Data were normalized to time-matched controls (n=5 an-
imals per time-point). *Signiﬁcantly different Pb0.05, **signiﬁcantly different Pb0.01.
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tive microglia also expresses CCL2, both in the latent and chronic
phase of experimental TLE.3.2. CCL4
In control animals the hippocampus was almost devoid of CCL4 IR
at all investigated time-points (Fig. 1B). After SE, expression of CCL4
IR could be observed in the hilar region of the hippocampus and
was most pronounced at 2 and 19 weeks (Fig. 1B). Indeed, quantiﬁca-
tion of CCL4 IR in the hilus revealed a more than 2-fold increase in
ROD, 2 and 19 weeks after SE (Fig. 2B). Although visual inspection in-
dicated increased CCL4 expression in the hilus also 4 and 8 weeks
after SE, this effect did not reach signiﬁcance upon quantiﬁcation
(Fig. 2B). Immunoﬂuorescence revealed that CCL4 IR co-localized
mostly with GFAP-positive astrocytes at both time points investigated
(Fig. 3C and D). Two weeks after SE, CCL4 IR was also detected in a
number of Vimentin-positive reactive astrocytes and endothelial
cells of the microvasculature (Fig. 3C). 19 weeks after SE, when
most Vimentin-positive reactive glia had disappeared, CCL4 IR was
still expressed in the Vimentin-positive endothelial cells (Fig. 3D).
CCL4 IR did not co-localize with neuronal marker NeuN nor with
the microglial marker Iba1. Interestingly, some CCL4 IR cells were
found in close proximity to neurons or microglia.
Our ﬁndings indicate that there is a biphasic up-regulation of CCL4
after SE. At 2 weeks after SE CCL4 is expressed by both reactive andGFAP positive astrocytes, whereas at 19 weeks after SE only GFAP-
positive astrocytes and the lining of blood vessels express CCL4.3.3. CCR5
CCR5 IR in controls and SE animals was predominantly found in
the hilar region of the hippocampus (Fig. 1D). Visual inspection
revealed increased hilar CCR5 IR at all time-points after SE. At 8 and
19 weeks after SE we also observed increased CCR5 IR in the molecu-
lar layer (ML) and the stratum radiatum (SR) of the hippocampus.
Quantiﬁcation of CCR5 IR in the hilar region of the hippocampus
revealed a signiﬁcant up-regulation of CCR5 at all time points investi-
gated (Fig. 2D). Double-labelling experiments showed that the major-
ity of GFAP-positive cells in the hilar region were CCR5-positive 2 and
19 weeks after SE (Fig. 4A, B). Some of the Vimentin-positive cells
detected in the hilus 2 weeks after SE also co-labelled with CCR5. At
19 weeks after SE no co-localization was detected anymore between
CCR5 and Vimentin concomitant with the general loss of Vimentin-
positive reactive glial cells. Even though Iba1-positive microglial
cells were found virtually hugging CCR5-positive cells, no actual co-
localization of these parameters was found at the two time points in-
vestigated. Additionally, CCR5 IR did not co-localize with NeuN
(Fig. 4A, B).
These ﬁndings show a long-term up-regulation of CCR5 IR in
reactive- and GFAP-positive astrocytes at least up to 19 weeks after
SE.
Fig. 3. CCL2 IR was predominantly found in neurons and CCL4 IR predominantly in (reactive) astrocytes and vascular endothelial cells.Fluorescent micrographs showing typical ex-
amples of double label immunoﬂuorescent (IF) experiments in the hilar region of the hippocampus 2 (A, C) and 19 weeks (B, D) after SE. Chemokines are in green, cell markers in
red. Insets (green, red, and merge) are confocal images of representative cells in the same region. CCL2 IF (A and B) co-localized mostly with neuronal marker NeuN and was also
found in a small subset of hilar Iba1-positive cells. CCL4 IF (C, D) was predominantly found in GFAP-positive astrocytes. CCL4 IF was also detected in a subset of Vimentin-positive
cells; at 2w these were both activated astrocytes and endothelial cells and at 19 w only endothelial cells of the microvasculature showed IF for both. Scale bar=100 μm.
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CCR1 IR was mostly detected in the hilar region of the hippocam-
pus in both SE and control animals (Fig. 1C). Quantiﬁcation revealed
that CCR1 IR was signiﬁcantly up-regulated 2, 4 and 8 weeks after
SE (Fig. 2D). This up-regulation was almost 5-fold 2 weeks after SE,
declined to about 2.5-fold after 8 weeks and was no longer signiﬁcant
19 weeks after SE (where only 3 of the 6 animals showed a moderate
increase in CCR1 expression). The pattern of CCR1 IR was highly sim-
ilar to that of CCR5 and IL-6 (compare Fig. 1C to D, E). Indeed, CCR1 IR
was found in the same glial subpopulations as CCR5, predominantly
in GFAP-positive and reactive astrocytes (data not shown). Our ﬁnd-
ings show an up-regulation of hilar CCR1 expression after SE that dis-
sipates over time.
3.5. IL-6
IL-6 IR was predominantly detected in the hilar region of the hip-
pocampus in all SE and control animals (Fig. 1E). Visual inspection
revealed increased hilar IL-6 IR at all time-points after SE. Interesting-
ly, at 8 and 19 weeks after SE we also observed increased IL-6 IR in the
molecular layer (ML) and the stratum radiatum (SR) of the hippo-
campus (Fig. 1E). This expression pattern is very similar to that of
CCR5 IR (compare Fig. 1D). Quantiﬁcation showed a marked increase
in IL-6 IR in the hilar region of the hippocampus at all four time pointsafter SE (Fig. 2E). This up-regulation was highest at 2 and 19 weeks
after SE, indicating a biphasic effect. IL-6 IR cells co-labelled with
both GFAP and Vimentin (Fig. 4C and D) two weeks after SE. At
19 weeks after SE the only Vimentin-positive cells that expressed IL-
6 IR were the cells lining the blood vessels of the hippocampus. No
co-localization of IL-6 IR was observed in the hippocampus with ei-
ther microglial or neuronal markers, although sometimes IL-6 IR
and NeuN- or Iba1-positive cells were detected in close proximity.
Our ﬁndings show persistent astroglial up-regulation of IL-6 after
SE. Additionally, we show that in response to SE, endothelial cells of
the microvasculature also express IL-6 at 2 and 19 weeks after the
treatment.3.6. Microglia cell marker Iba1
Using Iba1 as a microglial marker in the double label immunoﬂu-
orescence study we noticed a marked increase of Iba1 IR cells 2 weeks
after SE. This prompted us to investigate microgliosis during epilepto-
genesis in this animal model. Iba1-positive microglial cells were seen
scattered across the hippocampus in all animals investigated (Fig. 1F).
Most of these Iba1 IR cells displayed a resting ramiﬁed morphology
(Ladeby et al., 2005; Kadowaki et al., 2007). An up-regulation of
Iba1 IR cells was detected 2 and 4 weeks after SE (Fig. 2F). This in-
crease was most apparent in the hilar region of the hippocampus. A
Fig. 4. CCR5 and IL-6 IR was mainly found in GFAP- and Vimentin-positive glial cells.Fluorescent micrographs showing typical examples of double label immunoﬂuorescence (IF)
experiments in the hilar region of the hippocampus 2 and 19 weeks after SE. CCR5 and IL-6 are in green, cell markers in red. Insets are confocal images of representative cells in the
same region. CCR5 and IL-6 IF co-localized with GFAP- and Vimentin-positive astrocytes 2 w after SE. 19 w after SE CCR5 and IL-6 IF was found in GFAP-positive astrocytes and IL-6
was also detected in the Vimentin positive endothelial cells of the microvasculature. Scale bar=100 μm.
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morphology indicative of activated microglia.
At 8 and 19 weeks after SE no differences were detected between
SE and control animals in neither the number nor the morphology of
Iba1 IR cells. Our data shows microglial activation up to 4 weeks after
SE.
4. Discussion
Several lines of evidence indicate that the innate immune system
is up-regulated after seizures and in TLE (Vezzani, 2005; Fabene et
al., 2010; Vezzani et al., 2011). This up-regulation is thought to in-
clude cytokines as well as chemokines. Data on up-regulation of che-
mokines largely arises from studies where chemokine mRNA
expression was measured acutely after SE (hours, days) (Galasso et
al., 1998; Mennicken et al., 2002; Lee et al., 2007; van Gassen et al.,
2008; Wu et al., 2008; Louboutin et al., 2011). These studies indicate
that mRNA levels of particular chemokines are up-regulated acutely
after SE. It is important to show how such changes in mRNA translate
into effects on chemokine protein expression and to identify the cell
types responsible for their production. Therefore, the aim of the pre-
sent study was to monitor protein expression of key components in
chemokine signalling at the cellular level during the latent
(2–4 weeks) and chronic phase (19 weeks) in an experimental
model for TLE.4.1. SE induced an increase in CCL4, but not CCL2 expression
Our data show that protein levels of CCL4, but not CCL2, are up-
regulated in the hilus after SE (Fig. 2A, B). This shows that there is
speciﬁcity in the chemokine response following SE. In human TLE
samples, which are most comparable to the chronic phase in our ep-
ilepsy model, we previously found up-regulation of both CCL2 and
CCL4 mRNA (van Gassen et al., 2008). Our longitudinal data indicates
that CCL4, but not CCL2 signalling is involved in epileptogenesis. In-
terestingly, we found a biphasic up-regulation of CCL4 in SE animals.
The ﬁrst up-regulation is in the early latent phase (2 weeks after SE)
and appears to be due to increased expression in Vimentin-positive
(reactive) astrocytes, endothelial cells and GFAP-positive astrocytes.
The second CCL4 up-regulation is in the chronic phase (19 weeks
after SE) when a signiﬁcant proportion of the animals suffer from
SRS. This second increase in CCL4 can be attributed to expression in
GFAP-positive astrocytes and Vimentin-positive endothelial cells lin-
ing blood vessels and could be related to SRS activity. We have re-
cently shown that CCL4 protein expression in hippocampal
homogenates of patients with mTLE is also strongly up-regulated
(Kan and de Graan, unpublished), yet the cellular localisation of the
increase in CCL4 mRNA (Lee et al., 2007; van Gassen et al., 2008)
and protein expression in this tissue remains to be determined.
Based on our rat data it is likely that this will be in reactive and in
GFAP-positive astrocytes, and in vascular endothelial cells.
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protein expression in the hilus following SE (Fig. 2B). CCL2 expression
was largely found in neurons at all time-points investigated and not
in glial cells like CCL4. It is worth noting that we noticed a small num-
ber of activated microglial cells positive for CCL2 IR in the hilus of SE
animals (and not in their age-matched controls), but this increase
was not detectable by computerized image quantiﬁcation.
Previous animal studies have shown that up-regulation of CCL2
mRNA and protein occurs acutely after experimental SE in rats
(Gorter et al., 2006; Manley et al., 2007; Foresti et al., 2009). Gorter
et al. (2006) showed an initial increase in CCL2 mRNA in a longitudi-
nal expression proﬁling study of the rat hippocampus which, in line
with our results, disappeared in the latent and chronic phase of ex-
perimental TLE. In human mTLE patients, hippocampal CCL2 mRNA
(Lee et al., 2007; van Gassen et al., 2008; Wu et al., 2008) and protein
(Kan and de Graan, unpublished) expression is also signiﬁcantly in-
creased compared to autopsy controls. Possibly this increase in CCL2
expression in TLE patients and acutely after SE in animal models, is
related to the immediate, most likely microglial, reaction to seizure
activity.
Taken together, our study shows that only CCL4 expression is up-
regulated during the latent and chronic phase following SE and that
the site of chemokine production differs between CCL4 (mainly astro-
cytes) and CCL2 (mainly neurons). Thus, our data reveals speciﬁcity
in the chemokine response following SE in this animal model, and fa-
vours a role of CCL4 in the process of epileptogenesis.
4.2. SE induced a sustained increase in CCR5 and a transient increase in
CCR1 expression
To further investigate the possible role of CCL4 signalling in epi-
leptogenesis we analysed CCR1 and CCR5 expression at different
times after SE. Our data show that CCR5, the preferred receptor for
CCL4 (Murphy et al., 2000) is up-regulated at all time-points after
SE, thus in the latent as well as in the chronic phase. In contrast,
CCR1, a receptor with high afﬁnity for CCL2 (but also binding a frag-
ment of CCL4, (Guan et al., 2002)), was highly up-regulated at 2 and
4 weeks after SE, but returned to control levels in the chronic phase
(19 weeks after SE; Fig. 2C, D). We are not aware of other studies
reporting CCR1 expression after SE. Our data show that the increase
in CCR1 receptor expression is transient. This indicates that a possible
involvement of CCR1 in epileptogenesis is restricted to the latent
phase.
Up-regulation of CCR5 has previously been shown acutely after SE
(Galasso et al., 1998; Mennicken et al., 2002; Louboutin et al., 2011).
These authors found the up-regulation of CCR5 predominantly in
neurons and microglia, whereas in our study we only detected CCR5
protein in glial cells in the latent and chronic phase of TLE. Interest-
ingly, Liu et al. (2007) reported increased expression of another
CCL4 receptor, CCR8 after SE (Liu et al., 2007). This increase was ob-
served in interneurons acutely after SE, and in the chronic phase
also in GFAP positive glial cells. It remains to be determined whether
CCR5 expression shows a similar shift in cell type expression, as our
data does not exclude CCR5 expression in other cell types before the
ﬁrst 2 week time point.
Our data show that the CCR5 receptor is constitutively expressed
in the latent and chronic phase after SE. CCR5 is the preferred recep-
tor for CCL4, the chemokine which is also increased in the latent and
the chronic phase. Thus, our data indicate that CCL4/CCR5 signalling
may be important during epileptogenesis in the period before SRS
occur, as well as in the chronic epileptic phase. Interestingly, both
CCL4 and CCR5 are expressed in GFAP-positive astrocytes. Further ev-
idence for a role of astrocytes in epileptogenesis is the prolonged up-
regulation of IL-6, a cytokine previously implicated in experimental
and human TLE (Peltola et al., 2000; Liimatainen et al., 2009;
Vezzani et al., 2011). Our data is in line with several recent studiesemphasizing a role of astrocytes in epileptogenesis (Schwarcz,
2008; Seifert et al., 2010).
4.3. Potential role of CCL4 signalling in TLE
Expression levels of CCL4 and CCR5 in the healthy brain are very
low (Fig. 1B and D) (Biber et al., 2006). Our data suggests that SE in-
duces an increase in CCL4/CCR5 signalling both in the latent and
chronic phase of TLE. Based on literature this increased CCL4 signal-
ling may relate to two processes implicated in epileptogenesis: in-
creased glial glutamate release and disruption of the blood–brain
barrier (BBB). Increased glial CCL4 signalling may result in increased
Ca2+ inﬂux triggering glial glutamate release (Parpura et al., 1994;
Allen and Attwell, 2001; Biber et al., 2006; Kuijpers et al., 2010). In-
terestingly, the hilar astrocytes showing increased CCL4/CCR5 expres-
sion also display a marked reduction in expression of the glutamate
converting enzyme glutamine synthetase (GS) (Van der Hel, de
Graan, unpublished). Reduced GS expression is also found in the
human mTLE hippocampus (van der Hel et al., 2005). This suggests
that hilar astrocytes in TLE have reduced glutamate converting capac-
ity, and hence could secrete more glutamate in response to CCL4 sig-
nalling, thus contributing to hyperexcitability.
Increased CCL4 signalling may also relate to a loss of BBB integrity,
which has been implicated in epileptogenesis (Oby and Janigro, 2006;
van Vliet et al., 2007; Friedman et al., 2009). In human brain endothe-
lial cell cultures CCL4 has strong chemotactic properties toward T-
cells (Taub et al., 1993; Quandt and Dorovini-Zis, 2004). This process
can be triggered by TNFα and IL1β (Shukaliak and Dorovini-Zis,
2000), two inﬂammatory factors previously implicated in TLE
(Ravizza et al., 2007; Vezzani and Baram, 2007). Thus, the increase
in CCL4 expression we detected in vascular endothelial cells may re-
late to loss of BBB integrity by facilitating leukocyte entry through
the BBB (Fabene et al., 2008). A recent study by Louboutin et al.
(2011) provides compelling evidence that CCR5 signalling indeed af-
fects BBB integrity and epileptogenesis. These authors show in a rat
model for TLE that a reduction in CCR5 expression in circulating sys-
temic cells leads to a decrease in BBB disruption, neuronal death and
inﬂammation (Louboutin et al., 2011).
Although the pathways activated by CCL4/CCR5 signalling remain
to be elucidated, our data suggests a possible role for CCL4/CCR5 sig-
nalling in epileptogenesis. Our data supports the idea that CCR5 is a
target for the development of drugs to inhibit epileptogenesis. A
class of drugs of particular interest may be the CCR5 antagonists cur-
rently under investigation for HIV/AIDS therapy (Sayana and
Khanlou, 2009; Lenz and Rockstroh, 2010).
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